Crescent Biopharma (NASDAQ:CBIO) Now Covered by Analysts at HC Wainwright

Key Points

• HC Wainwright has initiated coverage on Crescent Biopharma (NASDAQ: CBIO) with a "buy" rating and a target price of $25.00, indicating a potential upside of 94.55% from its previous close.
• The company recently reported a loss of ($4.93) earnings per share for the last quarter, missing analysts' estimates by ($2.24).
• Crescent Biopharma's stock has seen significant volatility, with a recent opening price of $12.85 and a twelve-month high of $63.00.

Investment analysts at HC Wainwright began coverage on shares of Crescent Biopharma (NASDAQ:CBIO - Get Free Report) in a note issued to investors on Monday, Marketbeat reports. The firm set a "buy" rating and a $25.00 price target on the biopharmaceutical company's stock. HC Wainwright's price target would indicate a potential upside of 79.21% from the stock's current price. HC Wainwright also issued estimates for Crescent Biopharma's Q3 2025 earnings at ($1.29) EPS, Q4 2025 earnings at ($1.31) EPS, FY2025 earnings at ($8.43) EPS, Q1 2026 earnings at ($1.33) EPS, Q2 2026 earnings at ($1.36) EPS, Q3 2026 earnings at ($1.38) EPS, Q4 2026 earnings at ($1.42) EPS and FY2026 earnings at ($5.49) EPS.

Several other equities research analysts also recently issued reports on CBIO. Wall Street Zen downgraded shares of Crescent Biopharma from a "hold" rating to a "sell" rating in a research report on Saturday, August 2nd. Wedbush assumed coverage on shares of Crescent Biopharma in a report on Monday, July 14th. They set an "outperform" rating and a $27.00 target price for the company. Lifesci Capital upgraded shares of Crescent Biopharma to a "strong-buy" rating and set a $22.00 target price for the company in a report on Wednesday, June 18th. Stifel Nicolaus assumed coverage on shares of Crescent Biopharma in a report on Wednesday, June 25th. They set a "buy" rating and a $28.00 target price for the company. Finally, TD Cowen upgraded shares of Crescent Biopharma to a "strong-buy" rating in a research note on Friday, June 20th. One research analyst has rated the stock with a sell rating, three have given a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $25.50.

Crescent Biopharma Stock Performance

NASDAQ:CBIO traded up $0.02 during trading hours on Monday, hitting $13.95. The stock had a trading volume of 20,962 shares, compared to its average volume of 41,817. Crescent Biopharma has a one year low of $10.83 and a one year high of $63.00. The stock has a market cap of $272.72 million, a P/E ratio of -0.40 and a beta of 1.51. The firm has a 50 day moving average price of $13.88.

Hedge Funds Weigh In On Crescent Biopharma

Several large investors have recently modified their holdings of CBIO. Perceptive Advisors LLC bought a new position in Crescent Biopharma during the second quarter worth about $7,322,000. Frazier Life Sciences Management L.P. bought a new position in Crescent Biopharma during the second quarter worth about $7,322,000. Braidwell LP bought a new position in Crescent Biopharma during the second quarter worth about $4,221,000. BVF Inc. IL bought a new position in Crescent Biopharma during the second quarter worth about $22,400,000. Finally, Bank of America Corp DE bought a new position in Crescent Biopharma in the 2nd quarter valued at about $149,000. 75.19% of the stock is owned by institutional investors.

About Crescent Biopharma

Crescent Biopharma, Inc operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.